Why Keros Therapeutics, Inc.’s (KROS) Stock Is Up 5.92%
As of Thursday, November 12, Keros Therapeutics, Inc.’s KROS share price has surged by 5.92%, which has investors questioning if this is right time to sell.Rosalio Madrigal
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics to treat patients with disorders linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. It develops rinvatercept, which acts as a ligand trap and inhibits the biological effects of myostatin and activin A in Phase 1 clinical trials for Duchenne Muscular Dystrophy and Amyotrophic Lateral Sclerosis; and elritercept to target TGF-ß signaling pathways to address diseases that arise from ineffective hematopoiesis in Phase 3 clinical trials for Myelodysplastic Syndromes and Phase 2 clinical trials for Myelofibrosis. The company has collaboration and license agreements with Hansoh (Shanghai) Healthtech Co., Ltd. to develop, manufacture, and commercialize elritercept and licensed products containing elritercept; and Takeda Pharmaceuticals U.S.A., Inc. to develop, manufacture, and commercialize elritercept and certain derivative compounds. Keros Therapeutics, Inc. was incorporated in 2015 and is headquartered in Lexington, Massachusetts.
Commentary & Analysis
Why Keros Therapeutics, Inc.’s (KROS) Stock Is Down 10.34%
As of Thursday, November 05, Keros Therapeutics, Inc.’s KROS share price has dipped by 10.34%, which has investors questioning if this is right time to buy.Michael Rose
What You Need to Know About Keros Therapeutics, Inc.'s Q4 Earnings
Keros Therapeutics, Inc.'s fiscal Q4 earnings report was released on Thursday, November 05. Let's dive in to see if (KROS) missed or beat analyst's expectations.Rosalio Madrigal
Why Keros Therapeutics, Inc.’s (KROS) Stock Is Up 5.68%
As of Wednesday, September 09, Keros Therapeutics, Inc.’s KROS share price has surged by 5.68%, which has investors questioning if this is right time to sell.Jenna Brashear
Why Keros Therapeutics, Inc.’s (KROS) Stock Is Down 5.03%
As of Friday, August 28, Keros Therapeutics, Inc.’s KROS share price has dipped by 5.03%, which has investors questioning if this is right time to buy.Michael Rose
Financial Summary
| Share Statistics | KROS | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $197.8 | $218.8 | 28% |
|
| Shares Out (Mil) | 20.3 | 55.0 | 31% |
|
| Institutional Ownership | 96.4% | 92.8% | 70% |
|
| Float (Mil) | 17.6 | 42.0 | 27% |
|
| Beta | 1.19 | 0.96 | 70% |
|
| Avg Daily Volume (000s) | 219 | 546 | 46% |
|
| Price Change (52-week) |
(40.4%) | 44.0% | 24% |
|
| Growth | KROS | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 13.6% | na |
|
| Net Income (5yr) | 31.4% | (10.3%) | 86% |
|
| EPS (5yr) | 22.7% | 15.8% | 73 |
|
| Dividends (5yr) | na | 0.0% | 0% |
|
| Cash Flow (5yr) | (19.5%) | (15.7%) | 34% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 1 | 1 | 4 | |
| Current EPS | ($1.410) | ($3.350) | ($5.963) | |
| Month Ago EPS | ($1.780) | ($5.220) | ($6.616) | |
| # Rev Up | 0 | 2 | 2 | |
| # Rev Down | 2 | 1 | 1 | |
| Three Months Ago EPS | ($1.748) | ($5.142) | ($6.613) | |
| Year/Year Chg | (301.4%) | (245.7%) | (370.1%) | |
| Financials | KROS | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $41 | $41 | 18% |
|
| Net Income (TTM) (Mil) | ($62) | ($43) | 14% |
|
| EPS (TTM) | ($2.857) | ($1.500) | 12% |
|
| Operating Cash Flow (TTM) (Mil) | ($48) | ($35) | 10% |
|
| Net Cash Flow (TTM) (Mil) | ($434) | $-0 | 6% |
|
| Long-Term Debt (Q1) (Mil) | $12 | $4 | 29% |
|
| Enterprise Value (Q1) (Mil) | ($64) | $157 | 1% |
|
| Valuation | KROS | Industry Median |
Percentile (All Stocks) |
|
| P/B | 0.72 | 2.08 | 16% |
|
| P/E | na | 17.8 | na |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | na | 0.9 | na |
|
| Ratios | KROS | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | (82.4%) | 68.1% | 2% |
|
| Net Margin | (151.4%) | (50.8%) | 6% |
|
| ROA | (11.8%) | (47.4%) | 24% |
|
| ROE | (12.6%) | (52.5%) | 26% |
|
| Liabilities to Assets | 9.2% | 29.7% | 5% |
|
| F-Score | 3 | 3 | 18% |
|
Keros Therapeutics, Inc. did not pass any screens on 11/12/2026.
